Project Grant K24HL180292
Award Date 8/17/26
Completion Date 7/31/31
Dollars Obligated $133K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $865,711 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate beta-2 adrenergic receptor polymorphic variants as an endotype of salt-sensitive hypertension. The recipient will conduct translational research in humans and mice carrying either the risk (ARG16ARG/GLN27GLN) or non-risk (GLY16GLY/GLU27GLU) beta-2 adrenergic receptor diplotypes to distinguish between...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $131,886 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 1, 2025, with completion targeted for August 31, 2030. The project, titled "Volume and Patient-Oriented Research in Chronic Kidney Disease (VAPOR-CKD)," develops and validates clinical research methodologies to improve assessment of volume...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- Federal Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $268,500 to Brigham & Women's Hospital through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on September 11, 2025, for an R03 Project Grant titled "Incident Hemodialysis Electrolyte Analysis and Rhythm Trends (IHEART)." The award provides Dr. Katherine Ravi with resources, advanced training, and protected research time to...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $2.47 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. This award supports the development of a novel, kidney-draining lymph node (KLN)-targeted nanotherapeutic to treat crescentic glomerulonephritis (CGN), a...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded the Massachusetts General Hospital's Research Management Division $842,536 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms linking gestational diabetes mellitus (GDM) to increased coronary artery disease risk in women. The research integrates longitudinal electronic health records data spanning approximately 30 years postpartum for more than 208,000 women with GDM...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $152,777 on August 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of uremic toxins as mediators of cardiovascular-kidney-metabolic syndrome and peripheral artery disease in chronic kidney disease patients. The research examines tryptophan-derived uremic toxins, particularly kynurenine and its metabolites, as...
- The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $169,504 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize treatment gaps in GLP-1 receptor agonist access for low-income, working-age adults with obesity and evaluate the impact of state Medicaid policy expansions on cardiovascular health outcomes in this population. The project, designated K23HL183890, runs through May 31, 2031, with performance at...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $918,576 on June 24, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the mechanistic link between sociodemographic stressors and chronic kidney disease and end-stage kidney disease incidence in Black women. The research utilizes the Black Women's Health Study to model how cumulative allostatic load — chronic stress and...